Validation of epigenetic biomarkers of head and neck cancer progression--OLD

描述（由申请人提供）：头颈部鳞状细胞癌（HNSCC）是一种发病率和死亡率很高的疾病，没有可靠的预后、局部复发或存在癌前病变的指标。该项目的重点是验证表观遗传学，基于启动子甲基化的唾液冲洗生物标志物，这些标志物先前已在头颈部鳞状细胞癌（HNSCC）患者和未受影响的对照受试者中开发和发表。前期数据显示，这些标志物对头颈癌的检测具有特异性，初步数据显示，在HNSCC患者的预处理唾液冲洗液中检测到这些标志物是局部复发和生存不良的独立预后指标。我们将1)在HNSCC患者唾液冲洗液的单独验证队列中定义这些标记物，以确认与局部复发和较差的总生存率的关联。我们还将在临床口腔癌的恶性和癌前病变检测队列中验证和测试这些标记物，这些标记物之前是在纽约大学牙科学院的U54机制下收集的（U54DE014257, Dr. David Sirois）。

DESCRIPTION (provided by applicant): Head and Neck Squamous Cell Carcinoma (HNSCC) is a disease with significant morbidity and mortality, and without reliable indicators for prognosis, local recurrence, or presence of premalignant disease. This project is focused on validation of epigenetic, promoter methylation-based salivary rinse biomarkers that have been previously developed and published using a cohort of head and neck squamous cell carcinoma (HNSCC) patients and non-affected control subjects. Prior data shows these markers to be specific for head and neck cancer detection, and preliminary data show that detection of these markers in pretreatment salivary rinses in HNSCC patients is an independent prognostic indicator for local recurrence and poor survival. We will 1) define these markers in a separate validation cohort of salivary rinses from HNSCC patients to confirm association with local recurrence and poor overall survival. We will also 2) validate and test these markers in a clinical oral cancer detection cohort of malignant and premalignant lesions, respectively, previously collected under a U54 mechanism at the NYU College of Dentistry (U54DE014257, Dr. David Sirois). PUBLIC HEALTH RELEVANCE: This project is focused on validation of epigenetic, promoter methylation-based salivary rinse biomarkers that have been previously developed and published using a cohort of head and neck squamous cell carcinoma (HNSCC) patients and non-affected control subjects.